


Express Mail Label: EV038075370US
Date of Deposit: April 8, 2002



04-0702
Attorney Docket No.: 18242-508 CIP2 (VI-8 CIP2)

0420

7/1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Chapman, et al.
SERIAL NUMBER: 10/055,143 EXAMINER: Not Yet Assigned
FILING DATE: January 22, 2002 ART UNIT:
FOR: Method for Purifying a Biological Composition

Box IDS

Assistant Commissioner for Patents
Washington, D.C. 20231



30623

PATENT TRADEMARK OFFICE

TRANSMITTAL LETTER


Transmitted herewith for filing in the above-referenced patent application are the following documents:

1. Information Disclosure Statement (2 pages), in duplicate;
2. Modified Form 1449/PTO (3 pages), in duplicate;
3. Copies of cited references A1-A9, B1-B8, C1-C21; and
4. Return postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at 617-542-6000, Boston, Massachusetts.

The Commissioner is authorized to charge any fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 18242-508 CIP2 (VI-8 CIP2). A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,

Ser: 
Ivor R. Elrifi, Reg. No. 39,529
Attorney for Applicants


Date: April 8, 2002

c/o MINTZ, LEVIN, COHN, FERRIS
GLOVSKY AND POPEO, P.C.
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Chapman, et al.
SERIAL NUMBER: 10/055,143
FILING DATE: January 22, 2002
FOR: Method for Purifying a Biological Composition

EXAMINER: Not Yet Assigned
ART UNIT:



BOX IDS

Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application, copies of which are submitted herewith. The order of presentation of the references should not be construed as an indication of the importance of the references.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action based on the merits, in the above-identified case. Accordingly, no fee is required as set forth in 37 C.F.R. §1.97.

A copy of each of the above-identified information is enclosed unless otherwise indicated on the attached modified Form PTO-1449. It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed Form PTO-1449 to evidence that the cited information has been fully considered by the PATENT AND TRADEMARK OFFICE during the examination of this application.

Applicants: Chapman, et al.
U.S.S.N: 10/055,143

Please charge any fees that may be due, or credit any overpayment of same, to Deposit
Account No. 50-0311 (Reference No. 18242-508 CIP2 (VI-8 CIP2)).

Respectfully submitted,

For: [Signature] B No 45,409
Ivor R. Elrifi (Registration No. 39,529)
Attorney for the Applicants
c/o MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY and POPEO, P.C.

One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241

Dated: April 8, 2002

TRA 1653321v1

Please type a plus sign (+) in this box

+

PTO/SB (12-97)

Approved for use through 9/30/00. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	10/055,143
	Filing Date	01/22/2002
	First Named Inventor	Chapman
	Group Art Unit	
	Examiner Name	Not Yet Assigned
	Attorney Docket Number	18242-508 CIP2 (VI-8 CIP2)

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	A1	4,482,342	11/13/84	Lueptow, Richard M. et al.	494	21	
	A2	4,585,735	04/29/86	Meryman, Harold T. et al.	435	2	
	A3	4,668,214	05/26/87	Reeder, Gary G.	494	37	
	A4	5,250,303	10/05/93	Meryman, Harold T. et al.	424	533	
	A5	5,298,016	03/29/94	Gordon, Lucas S.	609	4	
	A6	5,601,972	02/11/97	Meryman, Harold R.	435	2	
	A7	5,671,135	09/23/97	Jorgensen, Glen et al.	364	181	
	A8	5,769,839	06/23/98	Carmen, Raleigh A. et al.	604	408	
	A9	5,906,915	05/25/99	Payrat, Jean-Marc et al.	435	2	


FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)		Date of Publication	Translation Yes No	
	B1	WO 91/04659	American Red Cross		18 April 1991	x	
	B2	WO 97/15685	Ernst-Ludwig Winnacker		01 May 1997	x	
	B3	WO 97/43649	Ernst-Ludwig Winnacker		20 November 1997	x	
	B4	WO 98/21944	New York Blood Center		28 May 1998	x	
	B5	WO 98/52629	Zymequest, Inc.		26 November 1998	x	
	B6	WO 00/18969	Pentose Pharmaceuticals, Inc.		06 April 2000	x	
	B7	WO 00/29849	Wallacoy		25 May 2000	x	
	B8	WO 00/33653	Haemonetics Corporation		15 June 2000	x	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C1	Valeri, et al. (2000). "Posttransfusion survival (24-hour) and hemolysis of previously frozen, deglycerolized RBCs after storage at 4°C for up to 14 days in sodium chloride alone or sodium chloride supplemented with additive solutions" <i>Transfusion</i> 40(11):1337-1340.
	C2	Moore, et al. (1993). "In vivo viability studies of two additive solutions in the postthaw preservation of red cells held for 3 weeks at 4°C" <i>Transfusion</i> 33(9): 709-712.
	C3	Houston, et al. (2000). "Transmission of BSE by blood transfusion in sheep" <i>Lancet</i> 356(9234): 999-1000.
	C4	Barclay, et al. (1999). "Distribution of cell-associated prion protein in normal adult blood determined by flow cytometry" <i>British Journal of Haematology</i> 107: 804-814.



OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C5	Civenni, <i>et al.</i> (1998). "In Vitro Incorporation of GPI-Anchored Proteins Into Human Erythrocytes and Their Fate in the Membrane" <i>Blood</i> 91(5): 1784-1792.
	C6	Hornsey, <i>et al.</i> (2000). "Leucofiltration, retention/generation of soluble prion and annexin V and storage of blood components", <i>Transfusion Science</i> 22: 75-76.
	C7	MacGregor, <i>et al.</i> (1999). "Application of a Time-Resolved Fluoroimmunoassay for the Analysis of Normal Prion Protein in Human Blood and Its Components" <i>Vox Sanguinis</i> 77: 88-96.
	C8	Meryman, <i>et al.</i> (1991). "Refrigerated Storage of Washed Red Cells" <i>Vox Sanguinis</i> 60: 88-98.
	C9	Prowse, <i>et al.</i> (1999). "Preliminary assessment of whole-blood, red-cell and platelet-leucodepleting filters for possible induction of prion release by leucocyte fragmentation during room temperature processing" <i>British Journal of Haematology</i> pages 240-247.
	C10	Chapman (2000). "Progress in Improving the Pathogen Safety of Red Cells Concentrates", <i>Vox Sanguinis</i> 78(suppl 2): 203-204.
	C11	Wagner, <i>et al.</i> (1991). "Approaches to the Reduction of Viral Infectivity in Cellular Blood Components and Single Donor Plasma" <i>Transfusion Medicine Reviews</i> 5(1): pp. 18-32.
	C12	Opinion on "The Safety Of Ruminant Blood With Respect To TSE Risks", pp. 2-66, adopted by the Scientific Steering Committee of the European Commission: Health & Consumer Protection Directorate - General, April 13-14, 2000.
	C13	Lazo, <i>et al.</i> (2000). "Screening of Parvovirus B19 by Polymerase Chain Reaction in Human Plasma Mini-Pools used in the Manufacture of Plas+®SD" <i>Annual Meeting of The American Society of Hematology 42nd Annual Meeting and Exposition: Abstract 244</i> (1 page). San Francisco, CA.
	C14	Purmal, <i>et al.</i> (2000). "Treatment of Baboon Red Cells with the Inactine™ Pathogen Inactivation Technology does not affect their in Vivo Survival or Antigenicity" <i>Annual Meeting of The American Society of Hematology 42nd Annual Meeting and Exposition: Abstract 255</i> (1 page). San Francisco, CA.
	C15	Purmal, <i>et al.</i> (2000). "Treatment Of Baboon Red Cells With The Inactine™ Pathogen Inactivation Technology Does Not Effect Their In Vivo Survival Or Antigenicity" <i>Annual Meeting of The American Society of Hematology 42nd Annual Meeting and Exposition: VITEX Poster Presentation</i> (1 page) San Francisco, CA.
	C16	Fast, <i>et al.</i> (2000). "Treatment of Human Leukocytes with Inactine™ Results in Loss of Function and Induction of Apoptosis" <i>Annual Meeting of The American Society of Hematology 42nd Annual Meeting and Exposition: Abstract 256</i> (1 page) San Francisco, CA.
	C17	Chapman, <i>et al.</i> (2000). "Preclinical Safety Assessment of Red Cells Virally Inactivated by Inactine™: Lack of Neoantigenicity" <i>Annual Meeting of The American Society of Hematology 42nd Annual Meeting and Exposition: Abstract 257</i> (1 page) San Francisco, CA.
	C18	AuBuchon, <i>et al.</i> (2000). "In Vivo Recovery of Red Blood Cells Virally Inactivated by Inactine™ and Stored for 28 Days" <i>Annual Meeting of The American Society of Hematology 42nd Annual Meeting and Exposition: Abstract 3538</i> (1 page). San Francisco, CA.
	C19	Davenport, <i>et al.</i> (2000). "Phase IV Study of Plas+®SD: Hepatitis A (HAV) and Parvovirus B19 (B19) Safety Results" <i>Annual Meeting of The American Society of Hematology 42nd Annual Meeting and Exposition: Abstract 1942</i> (1 page). San Francisco, CA.
	C20	"Asahi Chemical's Filter Removes Prions From Blood", <i>The Nikkei Industrial Daily</i> (Tuesday edition) Abstract, January 16, 2001, 1 page.

Express Mail Label No.: EV058075373US
Date of Deposit: April 8, 2002



Page 3 of 3

	C21	Opinion on, "The Implications of the Houston <i>et al.</i> Paper in the <i>Lancet</i> of 16 September 2000 on the Transmission of BSE by Blood Transfusion in Sheep." (The <i>Lancet</i> , Vol. 356, pp. 999-1000; 955-956; 1013), pp. 2-12, adopted by the Scientific Steering Committee of the European Commission: Health & Consumer Protection Directorate - General.
--	-----	---

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

TRA 1653279v1